Duchesne GM - Search Results

1

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, Martinez A, Pratt GR, Sandler H. Williams SG, et al. Among authors: duchesne gm. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):24-33. doi: 10.1016/j.ijrobp.2006.12.036. Int J Radiat Oncol Biol Phys. 2007. PMID: 17448868

2

What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy.

Duchesne GM, Peters LJ. Duchesne GM, et al. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8. doi: 10.1016/s0360-3016(99)00024-3. Int J Radiat Oncol Biol Phys. 1999. PMID: 10386630 No abstract available.

3

Radiation for prostate cancer.

Duchesne GM. Duchesne GM. Lancet Oncol. 2001 Feb;2(2):73-81. doi: 10.1016/S1470-2045(00)00223-0. Lancet Oncol. 2001. PMID: 11905798 Review.

4

Measurement of lung tumor volumes using three-dimensional computer planning software.

Bowden P, Fisher R, Mac Manus M, Wirth A, Duchesne G, Millward M, McKenzie A, Andrews J, Ball D. Bowden P, et al. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):566-73. doi: 10.1016/s0360-3016(02)02783-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 12062598

5

Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters.

Duchesne GM, Das R, Toye W, See A. Duchesne GM, et al. Australas Radiol. 2002 Dec;46(4):384-9. doi: 10.1046/j.1440-1673.2002.01091.x. Australas Radiol. 2002. PMID: 12452909

6

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study.

Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Spry N, Turner S, Woo H. Duchesne GM, et al. Urology. 2003 Jan;61(1):179-83. doi: 10.1016/s0090-4295(02)02005-8. Urology. 2003. PMID: 12559292

7

What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice.

Duchesne GM, Millar JL, Moraga V, Rosenthal M, Royce P, Snow R. Duchesne GM, et al. Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):986-91. doi: 10.1016/s0360-3016(02)04213-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12605977

8

What defines intermediate-risk prostate cancer? Variability in published prognostic models.

Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM. Williams SG, et al. Among authors: duchesne gm. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):11-8. doi: 10.1016/s0360-3016(03)00820-4. Int J Radiat Oncol Biol Phys. 2004. PMID: 14697415

9

Assessment of i-125 prostate implants by tumor bioeffect.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1405-13. doi: 10.1016/j.ijrobp.2004.01.047. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275726

10

Prostate implant evaluation using tumour control probability--the effect of input parameters.

Haworth A, Ebert M, Waterhouse D, Joseph D, Duchesne G. Haworth A, et al. Phys Med Biol. 2004 Aug 21;49(16):3649-64. doi: 10.1088/0031-9155/49/16/012. Phys Med Biol. 2004. PMID: 15446795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters